Cybin Corp updates investors on its IP development
Cybin Corp updates investors on its IP development
Mind Cure's iSTRYM digital therapeutics platform is designed to provide real-time data regarding patient care.
Health Canada issues its first Section 56 Exemption for psilocybin use to an Alberta resident.
Mind Cure announces a health-and-wellness supplement to support teen mental health.
Numinus announces the first legal extraction of psilocybe mushrooms in Canada by a public company.
MindMed increases its latest bought-deal financing to CAD$80 million.
Numinus acquires a Montreal-based provider of psychedelic-assisted psychotherapies.
MindMed continues to raise capital. This time issuing 11,364,000 units at CAD$4.40 for gross proceeds of CAD$50,001,600.
MindMed announces a successful pre-Investigational New Drug meeting with the FDA regarding its Project Lucy (LSD) research for anxiety.
Eleusis acquires a ketamine therapy provider and announces a new R&D program.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now